
Related Funds
Fund Name | Location |
Atlantica Ventures | Lagos, Lagos, Nigeria |
Beijing Xingchen Wenhua Chuanmei | Beijing, China, Pinggu |
Beta Bridge Capital | New Jersey, Princeton, United States |
CCFO Investments | Afghanistan, Kabul, Kabul Province |
Crossroads Capital | Colorado, Greenwood Village, United States |
DCapital | - |
Huaou Equity Investment | China, Hangzhou, Zhejiang |
Kunming Venture Capital | China, Kunming, Yunnan |
New York Presbyterian Ventures | New York, New York, United States |
Omron Ventures | Chiba, Japan, Minato |
ProVen VCT | England, London, United Kingdom |
Samsung Electronics | Seoul, Seoul-t'ukpyolsi, South Korea |
Sintokogio | Aichi Prefecture, Japan, Nagoya |
State Farm Ventures | Bloomington, Illinois, United States |
Stonehenge Partners Inc. | Columbus, Ohio, United States |
SuRo Capital | California, San Francisco, United States |
Sustainable Performance Group | Mclean, United States, Virginia |
TOM Capital Associates | Alberta, Calgary, Canada |
TPG Biotech | California, San Francisco, United States |
Yajie Shanghui | Beijing, China, Haidian |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
RVAC Medicines | $140M | 26 Apr 2022 | Singapore, Central Region, Singapore | ||
NiKang Therapeutics | $200M | 26 May 2021 | Wilmington, Delaware, United States | ||
Adcentrx Therapeutics | $50M | 28 Apr 2021 | San Diego, California, United States | ||
GrayBug | $80M | 20 Aug 2019 | Baltimore, Maryland, United States | ||
I-Mab Biopharma | $220M | 29 Jun 2018 | Shanghai | ||
$20M | 28 Jun 2018 | Shanghai | |||
$15M | 23 Apr 2018 | Jiang'an District, Hubei, China | |||
CMAB BioPharm | $34M | 02 Apr 2018 | Gusu District, Jiangsu, China | ||
CMAB BioPharm | $38M | 02 Jan 2018 | Gusu District, Jiangsu, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
RVAC Medicines | $140M | 26 Apr 2022 | Singapore, Central Region, Singapore | ||
NiKang Therapeutics | $200M | 26 May 2021 | Wilmington, Delaware, United States | ||
Adcentrx Therapeutics | $50M | 28 Apr 2021 | San Diego, California, United States | ||
GrayBug | $80M | 20 Aug 2019 | Baltimore, Maryland, United States | ||
I-Mab Biopharma | $220M | 29 Jun 2018 | Shanghai | ||
$20M | 28 Jun 2018 | Shanghai | |||
$15M | 23 Apr 2018 | Jiang'an District, Hubei, China | |||
CMAB BioPharm | $34M | 02 Apr 2018 | Gusu District, Jiangsu, China | ||
CMAB BioPharm | $38M | 02 Jan 2018 | Gusu District, Jiangsu, China |